Enanta Pharmaceuticals Inc (ENTA)
13.10
-1.49
(-10.21%)
USD |
NASDAQ |
May 07, 16:00
13.10
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (Quarterly): 36.37M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 36.37M |
| September 30, 2023 | 36.17M |
| June 30, 2023 | 42.99M |
| March 31, 2023 | 43.47M |
| December 31, 2022 | 40.90M |
| September 30, 2022 | 34.80M |
| June 30, 2022 | 39.09M |
| March 31, 2022 | 42.09M |
| December 31, 2021 | 48.55M |
| September 30, 2021 | 48.95M |
| June 30, 2021 | 46.99M |
| March 31, 2021 | 41.51M |
| December 31, 2020 | 36.66M |
| September 30, 2020 | 36.69M |
| June 30, 2020 | 34.68M |
| March 31, 2020 | 32.61M |
| December 31, 2019 | 32.78M |
| September 30, 2019 | 38.72M |
| June 30, 2019 | 34.46M |
| March 31, 2019 | 34.16M |
| December 31, 2018 | 34.88M |
| September 30, 2018 | 26.92M |
| June 30, 2018 | 28.49M |
| March 31, 2018 | 21.48M |
| December 31, 2017 | 17.96M |
| Date | Value |
|---|---|
| September 30, 2017 | 16.51M |
| June 30, 2017 | 15.41M |
| March 31, 2017 | 13.00M |
| December 31, 2016 | 12.53M |
| September 30, 2016 | 11.50M |
| June 30, 2016 | 10.78M |
| March 31, 2016 | 9.143M |
| December 31, 2015 | 9.033M |
| September 30, 2015 | 7.049M |
| June 30, 2015 | 6.253M |
| March 31, 2015 | 5.368M |
| December 31, 2014 | 4.519M |
| September 30, 2014 | 5.202M |
| June 30, 2014 | 4.553M |
| March 31, 2014 | 4.722M |
| December 31, 2013 | 4.263M |
| September 30, 2013 | 4.30M |
| June 30, 2013 | 4.039M |
| March 31, 2013 | 3.704M |
| December 31, 2012 | 4.798M |
| September 30, 2012 | 4.255M |
| June 30, 2012 | 4.925M |
| March 31, 2012 | 3.263M |
| December 31, 2011 | 2.672M |
| September 30, 2011 | 2.929M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
32.61M
Minimum
Mar 2020
48.95M
Maximum
Sep 2021
39.39M
Average
38.72M
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| Galectin Therapeutics Inc | 8.228M |
| Viking Therapeutics Inc | 24.10M |
| Akero Therapeutics Inc | 53.39M |
| 89bio Inc | 33.59M |